{{Drugbox
| IUPAC_name = 4-Propan-2-yl-2-[3-(trifluoromethyl)phenyl]morpholine
| image = Oxaflozane.svg
| width = 220

<!--Clinical data-->
| tradename = Conflictan
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 26629-86-8
| CAS_supplemental = <br />26629-86-7 ([[hydrochloride|HCl]])
| ATC_prefix = N06
| ATC_suffix = AX10
| PubChem = 432824
| ChemSpiderID = 382782
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = V4WLW77V5Q
| KEGG = D07340
| synonyms = CERM-1766

<!--Chemical data-->
| C=14 | H=18 | F=3 | N=1 | O=1 
| molecular_weight = 273.29 g/mol
| smiles = O1CCN(C(C)C)CC1c2cc(C(F)(F)F)ccc2
}}

'''Oxaflozane''' ([[International Nonproprietary Name|INN]]) (brand name '''Conflictan''') is an [[antidepressant]] and [[anxiolytic]] [[drug]] that was introduced by [[Solvay (company)|Solvay]] in [[France]] in 1982 for the treatment of [[major depression|depression]] but has since been [[discontinued]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA909|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=909–}}</ref><ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | page = 766 | isbn = 3-88763-075-0 | oclc = | doi = | url = https://books.google.com/books?id=5GpcTQD_L2oC&lpg=PA766&dq=oxaflozane%20conflictan&as_brr=3&pg=PA766#v=onepage&q=&f=false}}</ref><ref name="isbn0-8155-1144-2">{{cite book | author = Sittig, Marshall | title = Pharmaceutical manufacturing encyclopedia | publisher = Noyes Publications | location = Park Ridge, N.J., U.S.A | year = 1988 | page = 1122 | isbn = 0-8155-1144-2 | oclc = | doi = | url = https://books.google.com/books?id=XCsJgUnclbcC&lpg=PA1122&dq=oxaflozane%20conflictan&as_brr=3&pg=PA1122#v=onepage&q=&f=false}}</ref><ref name="BéguéBonnet-Delpon2008">{{cite book|author1=Jean-Pierre Bégué|author2=Daniele Bonnet-Delpon|title=Bioorganic and Medicinal Chemistry of Fluorine|url=https://books.google.com/books?id=QMVSvZ-R7I0C&pg=PA303|date=2 June 2008|publisher=John Wiley & Sons|isbn=978-0-470-28187-1|pages=303–}}</ref> It is a [[prodrug]] of [[flumexadol]] (''N''-dealkyloxaflozane; 2-(3-trifluoromethylphenyl)morpholine; CERM-1841 or 1841-CERM), which is reported to act as an [[receptor agonist|agonist]] of the [[serotonin]] [[5-HT1A receptor|5-HT<sub>1A</sub>]] (pK<sub>i</sub> = 7.1) and [[5-HT2C receptor|5-HT<sub>2C</sub>]] (pK<sub>i</sub> = 7.5) [[receptor (biochemistry)|receptor]]s and, to a much lesser extent, of the [[5-HT2A receptor|5-HT<sub>2A</sub>]] (pK<sub>i</sub> = 6.0) receptor.<ref name="BéguéBonnet-Delpon2008" /><ref name="pmid16160946">{{cite journal | author = Leysen DC | title = Selective 5-HT2C agonists as potential antidepressants | journal = IDrugs : the Investigational Drugs Journal | volume = 2 | issue = 2 | pages = 109–20 |date=February 1999 | pmid = 16160946 | doi = | url = }}</ref> In addition to its serotonergic properties, oxaflozane may also produce [[anticholinergic]] [[side effect]]s at high doses, namely in [[overdose]].<ref name="pmid1542141">{{cite journal |vauthors=Dutertre JP, Barbier P, Suc AL, Jonville AP, Autret E | title = Oxaflozane overdose in a child | journal = Journal of Toxicology. Clinical Toxicology | volume = 30 | issue = 1 | pages = 123–6 | year = 1992 | pmid = 1542141 | doi = 10.3109/15563659208994452| url = }}</ref>

==See also==
* [[Fluminorex]]
* [[Fludorex]]
* [[Fenfluramine]]
* [[Trifluoromethylphenylpiperazine|TFMPP]]
* [[Befiradol]]

==References==
{{Reflist|2}}

==Further reading==
* {{cite journal |vauthors=Rascol A, Maurel H, David J, Layani M | title = [Preliminary clinical results of a new non tricyclic antidepressive drug: oxaflozane] | language = French | journal = Thérapie | volume = 29 | issue = 1 | pages = 95–9 | year = 1974 | pmid = 4603757 | doi = | url = }}
* {{cite journal |vauthors=Hache J, Duchene-Marullaz P, Streichenberger G | title = [Pharmacological profile of a new non tricyclic antidepressant: oxaflozane (1,766 Cerm)] | language = French | journal = Thérapie | volume = 29 | issue = 1 | pages = 81–93 | year = 1974 | pmid = 4849381 | doi = | url = }}
* {{cite journal |vauthors=Constantin M, Pognat JF | title = Comparative study of oxaflozane urinary metabolism in man, the dog and the rat. Identification of the principal metabolites | journal = Arzneimittel-Forschung | volume = 29 | issue = 1 | pages = 109–14 | year = 1979 | pmid = 582104 | doi = | url = }}
* {{cite journal |vauthors=Bertolino A, palermo M, Porro V | title = Oxaflozane, a new nontricyclic antidepressant in the treatment of anxiety-depressions syndromes. | journal = Acta Ther | issue = 11 | pages = 209–218 | year = 1985 | pmid = | doi = | url = }}
* {{cite journal | author = Aguglia E | title = On the therapetic value of axaflozane: Its application in the treatment of emotional disturbances of the anxious-depressive type accompanied by somatic manifestations. | journal = Acta Ther | issue = 12 | pages = 259–267 | year = 1986 | pmid = | doi = | url = }}

{{Antidepressants}}
{{Anxiolytics}}
{{Serotonergics}}

[[Category:5-HT1A agonists]]
[[Category:5-HT2A agonists]]
[[Category:5-HT2C agonists]]
[[Category:Abandoned drugs]]
[[Category:Antidepressants]]
[[Category:Anxiolytics]]
[[Category:Morpholines]]
[[Category:Trifluoromethyl compounds]]


{{nervous-system-drug-stub}}